nizoral 20 mg/ml shampoo
stada arzneimittel ag - ketoconazole - shampoo - 20 mg/ml - ketokonatsoli
nizoral 2 % emulsiovoide
mcneil, a division of janssen- cilag oy - ketoconazole - emulsiovoide - 2 % - ketokonatsoli
nizoral 200 mg tabletti
janssen-cilag oy - ketoconazolum - tabletti - 200 mg - ketokonatsoli
nizoral 2 % emulsiovoide
orion oyj - ketoconazolum - emulsiovoide - 2 % - ketokonatsoli
nizoral blue 10 mg/ml shampoo
mcneil, a division of janssen- cilag oy - ketoconazolum - shampoo - 10 mg/ml - ketokonatsoli
nizoral 20 mg/ml shampoo
orifarm oy - ketoconazole - shampoo - 20 mg/ml - ketokonatsoli
nizoral 2 % emulsiovoide
ketoconazole - emulsiovoide - 2 % - ketokonatsoli
comirnaty
biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - rokotteet - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. käyttö tämä rokote tulee virallisten suositusten mukaisesti.
sandimmun neoral 100 mg/ml oraaliliuos
novartis finland oy - ciclosporin - oraaliliuos - 100 mg/ml - siklosporiini
sandimmun neoral 25 mg kapseli, pehmeä
novartis finland oy - ciclosporin - kapseli, pehmeä - 25 mg - siklosporiini